Pilot Study to Examine Correlation of Nab-Paclitaxel/Gemcitabine Pharmacokinetics with Cachexia

P
Patrick Loehrer, MD

Primary Investigator

Overview

The purpose of this study is to examine the relationship between body composition (i.e. muscle and fat mass) and the side effects of treatment with a commonly used chemotherapy regimen, specifically nab-paclitaxel and gemcitabine, in patients with advanced, metastatic or recurrent pancreatic cancer.

Description

The purpose of this study is to examine the relationship between body composition (i.e. muscle and fat mass) and the side effects of treatment with a commonly used chemotherapy regimen, specifically nab-paclitaxel and gemcitabine, in patients with advanced, metastatic or recurrent pancreatic cancer.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    pancreatic cancer,Cancer cachexia
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
Patients with locally advanced, metastatic or recurrent pancreatic ductal adenocarcinoma (PDAC)
Planned systemic first or second line therapy with Nab-P/G
ECOG Performance Status 0-2
Ability to provide written informed consent and HIPAA authorization
Adequate organ function
Exclusion Criteria
Inability or refusal to receive systemic therapy
Refusal to permit the study team to obtain follow up information from treating physicians? office or perform in person or remote follow up on available records


Additional Information:
Participants will be compensated for their participation.

Updated on 20 Nov 2022. Study ID: 1709056266 (IUSCC-0632)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center